Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is 1 of the 7 champion small-cap healthcare stocks to bargain according to hedge funds.

On March 12, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that the Phase 3 Enh3ance survey of DTX301, an experimental AAV8 cistron therapy for the attraction of ornithine transcarbamylase deficiency, yielded favourable findings.

Pressmaster/Shutterstock.com

DTX301-treated patients showed a statistically important and clinically meaningful 18% alteration successful 24-hour plasma ammonia compared to placebo astatine Week 36 of the randomised, double-blind, placebo-controlled signifier of the trial. Throughout Week 36, the mean ammonia AUC0-24 remained wrong the mean range.

Despite due existent medicine attraction and dietary restriction, 8 retired of 9 patients with abnormal ammonia AUC0-24 astatine baseline rapidly reached mean ammonia levels, which were often maintained during this attraction period.

On March 12, JPMorgan reduced its terms people connected Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $120 to $74. The steadfast maintained an Overweight standing connected the shares. JPMorgan noted that existent stock levels bash not bespeak meaningful worth for cardinal pipeline assets, including GTX-102.

It added that updated estimates besides incorporated reduced expectations for setrusumab pursuing a caller setback, portion emphasizing that affirmative objective information volition beryllium important to thrust aboriginal upside.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops caller therapies, with a absorption connected identifying, acquiring, and commercializing products for uncommon and ultra-rare familial diseases. It has a beardown accent connected cistron therapy and covers assorted stages of objective trials. The institution is presently going done precocious currency pain with the purpose of turning profitable from 2027 onwards.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.